Clinical ink Introduces Breakthrough Solution to Drastically Reduce Study Build Timelines

Innovative eCOA Technology Sets New Standard for Speed, Efficiency, and Accuracy in Study Build Process
 

Winston Salem, NC – Clinical ink, a global life science technology company, is setting a new industry benchmark in advancing study build timelines. Harnessing the power of the latest eCOA technology, Clinical ink can now reduce study build timelines to as little as 10 days.

Clinical ink’s scalable software solution offers enhanced precision right from the start to ensure trial success. Key features of Clinical ink cutting-edge eCOA technology include:

• What You See Is What You Get (WYSIWYG) Design
  Streamline the instrument build process with a codeless GUI-driven design interface providing immediate and intuitive visibility into what sites and subjects will see.
   
• Flexibility by Design
  Gain unprecedented flexibility with build tools that support collaborative work, enabling teams to concurrently work and alter a study’s design as needed.
   
• Direct Translation System Integration
  Eliminate the need for manual file distribution and text copy through cumbersome channels, promoting efficiency.
   
• Custom Library
  Dedicated repository of approved and validated content tailored to your specific needs.

“Setting a 10-day benchmark in study build timelines is proof of the strength of the latest Clinical ink eCOA technology,” comments Megan Petrylak, EVP, Clinical Operations. “Clinical ink is redefining speed and raising the bar for efficiency and accuracy, ensuring that clinical study development is agile and meticulous.“

Through a seamless, codeless user interface with direct integrations, Clinical ink eCOA advancements ensure a streamlined and precise study build process. These are the latest advancements delivered by Clinical ink, following its recently unveiled Data Management services, to further enhance its comprehensive range of eCOA, direct data capture, patient engagement, and digital biomarker solutions.

About Clinical ink

Clinical ink is the global life science company bringing together data, technology, and patient-centric research. Our deep therapeutic area expertise, coupled with Direct Data Capture, eCOA, eConsent, Telehealth, and Digital Biomarkers advancements, including the use of Continuous Glucose Monitoring for the detection of hypoglycemia, support the next generation of clinical trials and ultimately the clinical management of patients.